BioNTech (BNTX) COVID Driven Revenue Misses, Guidance Lowered Amidst Leadership Transition and Incremental Pipeline Updates

Equity Research 5 August 2026 | 6:01AM EDT

BioNTech (BNTX): COVID Driven Revenue Misses, Guidance Lowered Amidst Leadership Transition and Incremental Pipeline Updates

A day after announcing its CEO replacement, BNTX underperformed biotech peers Asad Haider, CFA | (-1% vs XBI +3%) on the back of an a 2Q26 earnings print which saw a COVID-driven Goldman Sachs & Co. LLC

revenue miss (€106mn vs GSe €156 / Visible Alpha consensus €160) and cut to Nick Jennings | guidance for FY 2026. Regarding the more important oncology pipeline, the updates Goldman Sachs & Co. LLC were largely incremental in our view. With a cash balance of €16.6bn, BNTX is executing on its $1bn share repurchase program (purchasing $152mn so far), and Jeff Su | Goldman Sachs & Co. LLC notes they have BD appetite for assets that underpin their strategy and complementary to the current portfolio, with later clinical stage or commercial assets in scope.

On the forward event path, the company highlighted 3 late-stage data events anticipated for 2H26: gotistobart in sq NSCLC, FixVac BNT113 in head & neck cancer, and T-Pam in breast cancer. Additionally, two data events that were previously expected for 2026 were pushed to 2027: Ph3 pumitamig in TNBC in China and Ph2 gotistobart in 2L CRPC. Externally, we are watching for readacross from SMMT’s ivonescimab (PD1xVEGF bispecific) global Phase 3 HARMONi-3 frontline NSCLC squamous cohort final progression-free survival (PFS) and interim OS data in 2H26.

We update our DCF based 12-month price target to $128 (vs. $133 prior), driven primarily by the updated lower COVID revenue estimates. We remain Buy rated, as our outlook on the stock is driven by the broad oncology portfolio, which has continued to progress.

What Stood Out To Us n CEO transition. Guido Oelkers (former Sobi CEO) will take over as CEO by February 1, 2027 at the latest, succeeding co-founder Ugur Sahin, who has led the company since its founding. Oelkers served as CEO of Sobi for nine years and brings experience in scaling biopharmaceutical operations globally, commercializing innovative products, particularly in the US market. n Guidance update. BNTX lowered its full-year 2026 revenue guidance to €1.6bn – €1.9bn, a reduction of approximately €400mn at the midpoint versus prior guidance. ~80% of the cut was attributed to weaker global COVID-19 vaccine demand driven by softer vaccination rates. Germany’s decision to utilize previously manufactured on-stock vaccine doses for the upcoming vaccination season disproportionately impacts BNTX given that Germany is a direct market (versus other geographies managed by partner Pfizer). Additionally, the

Goldman Sachs does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. For Reg AC certification and other important disclosures, see the Disclosure Appendix, or go to Analysts employed by non-US affiliates are not registered/qualified as research analysts with FINRA in the U.S.

European Medicines Agency’s May recommendation allowing use of the previous US vaccine formula as an alternative to newly recommended XFG variant-adapted vaccines added further pressure on demand. The remaining ~20% of the revenue cut stems from a milestone payment tied to an out-licensed R&D program that is no longer expected to be recognized in 2026. On the cost side, BNTX lowered adjusted R&D expense guidance to €2.0bn – €2.3bn, reflecting pipeline prioritization, favorable partner cost-sharing dynamics, and continued optimization — with management noting these savings are expected to persist into future years. Adjusted SG&A guidance was left unchanged at €700mn – €800mn, as the company continues to build commercial capabilities ahead of anticipated oncology launches. Management noted that the majority of 2026 revenue remains back-half weighted, with Q3 expected to include the €613mn BMY collaboration payment. n Gotistobart (CTLA-4). The Ph3 interim analysis in 2L squamous non-small cell lung…